August 15, 2022
PAR-21-206 - Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)
National Cancer Institute (NCI)
This Notice extends the expiration date for PAR-21-206, Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional) by the addition of a Standard Application Due Date.
The following section has been modified:
Part 1. Overview Information, Key Dates
Currently, it reads:
|
Application Due Dates |
Review and Award Cycles |
||||
|
New |
Renewal / Resubmission / Revision (as allowed) |
AIDS |
Scientific Merit Review |
Advisory Council Review |
Earliest Start Date |
|
June 05, 2021 * |
July 05, 2021 * |
Not Applicable |
November 2021 |
January 2022 |
April 2022 |
|
October 05, 2021 * |
November 05, 2021 * |
Not Applicable |
March 2022 |
May 2022 |
July 2022 |
|
February 05, 2022 * |
March 05, 2022 * |
Not Applicable |
July 2022 |
October 2022 |
December 2022 |
|
June 05, 2022 * |
July 05, 2022 * |
Not Applicable |
November 2022 |
January 2023 |
April 2023 |
|
October 05, 2022 * |
November 05, 2022 * |
Not Applicable |
March 2023 |
May 2023 |
July 2023 |
|
February 05, 2023 * |
March 05, 2023 * |
Not Applicable |
July 2023 |
October 2023 |
December 2023 |
|
June 05, 2023 * |
July 05, 2023 * |
Not Applicable |
November 2023 |
January 2024 |
April 2024 |
|
October 05, 2023 * |
November 05, 2023 * |
Not Applicable |
March 2024 |
May 2024 |
July 2024 |
Expiration Date: January 08, 2024
Revised to read (in bold italics):
|
Application Due Dates |
Review and Award Cycles |
||||
|
New |
Renewal / Resubmission / Revision (as allowed) |
AIDS |
Scientific Merit Review |
Advisory Council Review |
Earliest Start Date |
|
June 05, 2021 * |
July 05, 2021 * |
Not Applicable |
November 2021 |
January 2022 |
April 2022 |
|
October 05, 2021 * |
November 05, 2021 * |
Not Applicable |
March 2022 |
May 2022 |
July 2022 |
|
February 05, 2022 * |
March 05, 2022 * |
Not Applicable |
July 2022 |
October 2022 |
December 2022 |
|
June 05, 2022 * |
July 05, 2022 * |
Not Applicable |
November 2022 |
January 2023 |
April 2023 |
|
October 05, 2022 * |
November 05, 2022 * |
Not Applicable |
March 2023 |
May 2023 |
July 2023 |
|
February 05, 2023 * |
March 05, 2023 * |
Not Applicable |
July 2023 |
October 2023 |
December 2023 |
|
June 05, 2023 * |
July 05, 2023 * |
Not Applicable |
November 2023 |
January 2024 |
April 2024 |
|
October 05, 2023 * |
November 05, 2023 * |
Not Applicable |
March 2024 |
May 2024 |
July 2024 |
|
February 05, 2024* |
March 05, 2024 * |
Not Applicable |
July 2024 |
October 2024 |
December 2024 |
Expiration Date: May 08, 2024
All other aspects of this FOA remain unchanged.
Scientific/Research Contact(s)
Miguel R. Ossandon, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-5714
Email: [email protected]
Darrell Tata, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-5894
Email: [email protected]
Peer Review Contact(s)
Yuanna Cheng, Ph.D.
Center for Scientific Review (CSR)
Telephone: 301-435-1195
Email: [email protected]
Financial/Grants Management Contact(s)
Shane Woodward
National Cancer Institute (NCI)
Telephone: 240-276-6303
Email: [email protected]
and Human Services (HHS)
